Compare · CARM vs JNJ
CARM vs JNJ
Side-by-side comparison of Carisma Therapeutics Inc. (CARM) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CARM and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ carries a market cap of $617.78B.
- Over the past year, CARM is down 50.0% and JNJ is up 49.9% - JNJ leads by 99.9 points.
- JNJ has hit the wire 18 times in the past 4 weeks while CARM has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 8 for CARM).
- Company
- Carisma Therapeutics Inc.
- Johnson & Johnson
- Price
- $0.15-46.08%
- $256.46+0.24%
- Market cap
- -
- $617.78B
- 1M return
- +0.00%
- +0.96%
- 1Y return
- -50.00%
- +49.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 18
- Recent ratings
- 8
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CARM
- SEC Form 15-12G filed by Carisma Therapeutics Inc.
- SEC Form EFFECT filed by Carisma Therapeutics Inc.
- SEC Form EFFECT filed by Carisma Therapeutics Inc.
- SEC Form EFFECT filed by Carisma Therapeutics Inc.
- SEC Form EFFECT filed by Carisma Therapeutics Inc.
- SEC Form S-8 POS filed by Carisma Therapeutics Inc.
- SEC Form S-8 POS filed by Carisma Therapeutics Inc.
- SEC Form S-8 POS filed by Carisma Therapeutics Inc.
- SEC Form S-8 POS filed by Carisma Therapeutics Inc.
- SEC Form S-8 POS filed by Carisma Therapeutics Inc.
Latest JNJ
- Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
- Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
- Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
- SEC Form 10-Q filed by Johnson & Johnson
- TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
- Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System